Literature DB >> 19437133

3-Hydroxyflavone inhibits endogenous Aurora B and induces growth inhibition of cancer cell line.

Qingyu Lang1, Haoxing Zhang, Jie Li, Fang Xie, Yifeng Zhang, Bo Wan, Long Yu.   

Abstract

The Aurora kinases play a critical role in mitosis and have been suggested as promising targets for cancer therapy due to their frequent overexpression in a variety of tumors. Compared with established inhibitors of cell division such as the anti-tubulins, novel agents target mitotic enzymes and show similar efficacy but with fewer side effects. Several small-molecule inhibitors of Aurora kinases have been developed as anticancer agents, some of which have progressed to early clinical evaluation. Here we identified 3-hydroxyflavone as a novel Aurora B inhibitor through high throughput screening. 3-Hydroxyflavone showed potent inhibition to Aurora B with the IC(50) on a nanomolar basis in the enzyme-based kinase activity assay. In the cell-based western blotting analysis, 3-hydroxyflavone dramatically decreased the phosphorylation level of Histone H3 on the site of serine 10, demonstrating the potent endogenous Aurora B activity inhibition in cell level. The followed cell image analysis provided the consist result. To make it clear whether 3-hydroxyflavone inhibited Aurora B by direct binding or not, SPR analysis was carried out to measure the affinity of interaction between Aurora B protein and 3-hydroxyflavone and the result proved the binding with high affinity. Usually Aurora activity suppression induced cancer cell proliferation inhibition. Colony formation and cell viability with/without treatment of 3-hydroxyflavone were measured using CCK-8. The growth suppression under 3-hydroxyflavone present and the growth recovery after being released gave strong evidence that presence of 3-hydroxyflavone efficiently inhibited the fast growth of cancer cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19437133     DOI: 10.1007/s11033-009-9562-y

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  18 in total

1.  Mitotic kinase expression and colorectal cancer progression.

Authors:  H Katayama; T Ota; F Jisaki; Y Ueda; T Tanaka; S Odashima; F Suzuki; Y Terada; M Tatsuka
Journal:  J Natl Cancer Inst       Date:  1999-07-07       Impact factor: 13.506

Review 2.  Mitotic kinases as regulators of cell division and its checkpoints.

Authors:  E A Nigg
Journal:  Nat Rev Mol Cell Biol       Date:  2001-01       Impact factor: 94.444

Review 3.  The cellular geography of aurora kinases.

Authors:  Mar Carmena; William C Earnshaw
Journal:  Nat Rev Mol Cell Biol       Date:  2003-11       Impact factor: 94.444

4.  A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines.

Authors:  S Sen; H Zhou; R A White
Journal:  Oncogene       Date:  1997-05-08       Impact factor: 9.867

5.  Aurora C is directly associated with Survivin and required for cytokinesis.

Authors:  Xiaomei Yan; Lihuan Cao; Qiang Li; Yanhua Wu; Haoxing Zhang; Hexige Saiyin; Xianghua Liu; Xuqing Zhang; Qinghua Shi; Long Yu
Journal:  Genes Cells       Date:  2005-06       Impact factor: 1.891

Review 6.  Dynamic changes in nuclear architecture during mitosis: on the role of protein phosphorylation in spindle assembly and chromosome segregation.

Authors:  E A Nigg; A Blangy; H A Lane
Journal:  Exp Cell Res       Date:  1996-12-15       Impact factor: 3.905

Review 7.  Genetic instabilities in human cancers.

Authors:  C Lengauer; K W Kinzler; B Vogelstein
Journal:  Nature       Date:  1998-12-17       Impact factor: 49.962

Review 8.  Targeting Aurora-2 kinase in cancer.

Authors:  Steven L Warner; David J Bearss; Haiyong Han; Daniel D Von Hoff
Journal:  Mol Cancer Ther       Date:  2003-06       Impact factor: 6.261

9.  Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores.

Authors:  Claire Ditchfield; Victoria L Johnson; Anthony Tighe; Rebecca Ellston; Carolyn Haworth; Trevor Johnson; Andrew Mortlock; Nicholas Keen; Stephen S Taylor
Journal:  J Cell Biol       Date:  2003-04-28       Impact factor: 10.539

10.  VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo.

Authors:  Elizabeth A Harrington; David Bebbington; Jeff Moore; Richele K Rasmussen; Abi O Ajose-Adeogun; Tomoko Nakayama; Joanne A Graham; Cecile Demur; Thierry Hercend; Anita Diu-Hercend; Michael Su; Julian M C Golec; Karen M Miller
Journal:  Nat Med       Date:  2004-02-22       Impact factor: 53.440

View more
  5 in total

1.  RNA interference targeting CITRON can significantly inhibit the proliferation of hepatocellular carcinoma cells.

Authors:  Yinghui Fu; Jian Huang; Ke-Sheng Wang; Xin Zhang; Ze-Guang Han
Journal:  Mol Biol Rep       Date:  2010-04-06       Impact factor: 2.316

Review 2.  Toward Carbon Monoxide-Based Therapeutics: Critical Drug Delivery and Developability Issues.

Authors:  Xingyue Ji; Krishna Damera; Yueqin Zheng; Bingchen Yu; Leo E Otterbein; Binghe Wang
Journal:  J Pharm Sci       Date:  2016-01-06       Impact factor: 3.534

3.  Secretory TAT-peptide-mediated protein transduction of LIF receptor α-chain distal cytoplasmic motifs into human myeloid HL-60 cells.

Authors:  Q Sun; J Xiong; J Lu; S Xu; Y Li; X P Zhong; G K Gao; H Q Liu
Journal:  Braz J Med Biol Res       Date:  2012-06-21       Impact factor: 2.590

Review 4.  3-Hydroxyflavone derivatives: promising scaffolds for fluorescent imaging in cells.

Authors:  Xueke Zhao; Xiang Li; Shuyu Liang; Xiongwei Dong; Zhe Zhang
Journal:  RSC Adv       Date:  2021-08-27       Impact factor: 4.036

5.  Selective Activation of ZAK β Expression by 3-Hydroxy-2-Phenylchromone Inhibits Human Osteosarcoma Cells and Triggers Apoptosis via JNK Activation.

Authors:  Chien-Yao Fu; Ing-Shiow Lay; Marthandam Asokan Shibu; Yan-Shen Tseng; Wei-Wen Kuo; Jaw-Ji Yang; Tso-Fu Wang; B Mahalakshmi Bharath; Yu-Lan Yeh; Chih-Yang Huang
Journal:  Int J Mol Sci       Date:  2020-05-09       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.